Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overcoming disparities in hepatocellular carcinoma outcomes in First Nations Australians: a strategic plan for action.
Howell J, Combo T, Binks P, Bragg K, Bukulatjpi S, Campbell K, Clark PJ, Carroll M, Davies J, de Santis T, Muller KR, Nguyen B, Olynyk JK, Shackel N, Valery PC, Wigg AJ, George J, Roberts SK. Howell J, et al. Among authors: wigg aj. Med J Aust. 2024 Sep 2;221(5):230-235. doi: 10.5694/mja2.52395. Epub 2024 Aug 6. Med J Aust. 2024. PMID: 39107943 No abstract available.
Additive impact of pre-liver transplant metabolic factors on survival post-liver transplant.
Adams LA, Arauz O, Angus PW, Sinclair M, MacDonald GA, Chelvaratnam U, Wigg AJ, Yeap S, Shackel N, Lin L, Raftopoulos S, McCaughan GW, Jeffrey GP; Australian New Zealand Liver Transplant Study Group. Adams LA, et al. Among authors: wigg aj. J Gastroenterol Hepatol. 2016 May;31(5):1016-24. doi: 10.1111/jgh.13240. J Gastroenterol Hepatol. 2016. PMID: 26589875
Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Lubel J, Strasser S, Stuart KA, Dore G, Thompson A, Pianko S, Bollipo S, Mitchell JL, Fragomeli V, Jones T, Chivers S, Gow P, Iser D, Levy M, Tse E, Gazzola A, Cheng W, Nazareth S, Galhenage S, Wade A, Weltman M, Wigg A, MacQuillan G, Sasadeusz J, George J, Zekry A, Roberts SK; Australian Liver Association Clinical Research Network (ALA CRN). Lubel J, et al. Antivir Ther. 2017;22(8):699-710. doi: 10.3851/IMP3168. Antivir Ther. 2017. PMID: 28422043
Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy.
Roberts SK, Lim R, Strasser S, Nicoll A, Gazzola A, Mitchell J, Siow W, Khoo T, Hamarneh Z, Weltman M, Gow P, Janko N, Tse E, Mishra G, Cheng EH, Levy M, Cheng W, Sood S, Skoien R, Mitchell J, Zekry A, George J, MacQuillan G, Wigg A, Stuart K, Sievert W, McCaughan G; ALA Clinical Research Network. Roberts SK, et al. Clin Gastroenterol Hepatol. 2018 Feb;16(2):268-277. doi: 10.1016/j.cgh.2017.09.063. Epub 2017 Oct 16. Clin Gastroenterol Hepatol. 2018. PMID: 29050991
Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15).
McCaughan GW, Thwaites PA, Roberts SK, Strasser SI, Mitchell J, Morales B, Mason S, Gow P, Wigg A, Tallis C, Jeffrey G, George J, Thompson AJ, Parker FC, Angus PW; Australian Liver Association Clinical Research Network. McCaughan GW, et al. Among authors: wigg a. Aliment Pharmacol Ther. 2018 Feb;47(3):401-411. doi: 10.1111/apt.14404. Epub 2017 Dec 5. Aliment Pharmacol Ther. 2018. PMID: 29205432
91 results